Drugs / GLS-6150
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03674125 | Sep 2018 → Apr 2020 | hepatitis C virus infection | GeneOne Life Science, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLS-6150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03674125 ↗ |
| Modality | Vaccine | “GLS-6150 is a DNA plasmid vaccine” NCT03674125 ↗ |